Helix BioPharma (FRA:HBP0) 1-Year Share Buyback Ratio : -22.40% (As of Jan. 2025 )

View and export this data going back to . Start your Free Trial

What is Helix BioPharma 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Helix BioPharma's current 1-Year Share Buyback Ratio was -22.40%.

FRA:HBP0's 1-Year Share Buyback Ratio is ranked worse than
60.4% of 1202 companies
in the Biotechnology industry
Industry Median: -13.65 vs FRA:HBP0: -22.40

Competitive Comparison of Helix BioPharma's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, Helix BioPharma's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix BioPharma's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Helix BioPharma 1-Year Share Buyback Ratio Calculation

Helix BioPharma's 1-Year Share Buyback Ratio for the quarter that ended in Jan. 2025 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Jan. 2024 )	-	Shares Outstanding (EOP) (Jan. 2025 ))	/	Shares Outstanding (EOP) (Jan. 2024 )
	=	(43.335	-	53.022)	/	43.335
	=	-22.4%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma (FRA:HBP0) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Helix BioPharma 1-Year Share Buyback Ratio Related Terms

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (FRA:HBP0) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

HBP:Canada

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.

Helix BioPharma Headlines

No Headlines